Software Engineer
Chai Discovery
Software Engineer
Chai Discovery
AI foundation models for molecular interactions
Chai Discovery builds the computer-aided design suite for molecules. Eli Lilly, GSK, Pfizer, Bristol Myers Squibb, argenx and Novartis all use Chai to power drug discovery programs. AI is reinventing life sciences the same way it reinvented software engineering, and our team is building that future.
We train frontier models that learn the underlying foundations of biochemical structure and interaction. We pair this with a computational workspace to iterate on molecules from idea to medicine, helping scientists move faster and develop medicines beyond the reach of existing methods.
We value diverse perspectives and are ready to find greatness in unexpected places.
Build the platform that shortens the time it takes researchers and engineers to test ideas, ship software, and learn from experiments. We believe the software factory is just as important as the software itself, and you will build that factory for people and agents, including:
Shipping the research platform where people and agents launch experiments, compare results, and decide what to try next.
Designing systems that let coding agents take on more development, testing, and code review.
Setting up better development environments, faster tests, and reliable deploys.
We look for strong systems engineering, developer taste, and a record of making other technical people more effective. You understand how researchers and engineers work, can go deep into the systems they depend on, and build tools they want to use.
The opportunity to work at the vanguard of AI research and frontier biology, with world-class people, on a mission that matters. We protect and promote a culture of high velocity and ownership. We compensate our team accordingly.
AI foundation models for molecular interactions
Chai Discovery builds AI foundation models that predict and influence interactions between biochemical molecules, including proteins, DNA, RNA, small molecules, and covalent modifications. Its flagship model, Chai 1, is a multimodal tool available through a free web interface for both academic and commercial drug-discovery work. Revenue comes from commercial licensing and partnerships with pharmaceutical companies that want to embed the AI capabilities into their research pipelines. The goal is to accelerate biotechnology and pharma research by providing accessible AI-driven predictions of molecular interactions that guide experiments and design.
Explore more opportunities at Chai Discovery